Altered erythropoiesis and iron metabolism in carriers of thalassemia

European Journal of Haematology

Volumn 94, Issue 6, 2015, Pages 511-518

  Guimarães, Jacqueline S ^a,b   Cominal, Juçara G ^a   Silva Pinto, Ana Cristina ^a   Olbina, Gordana ^c   Ginzburg, Yelena Z ^d   Nandi, Vijay ^d   Westerman, Mark ^c   Rivella, Stefano ^b   De Souza, Ana Maria ^a,e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LLC   (United States)

^d NEW YORK BLOOD CENTER   (United States)

^e Lab: Hematologia   (Brazil)

Author keywords

Erythropoiesis; Erythropoietin; Ferritin; GDF15; Hepcidin; Iron metabolism; Soluble transferrin receptor; Thalassemia

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; TRANSFERRIN RECEPTOR; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; IRON;

ALPHA THALASSEMIA; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INVESTIGATIVE PROCEDURES; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; RED CELL DISTRIBUTION WIDTH; BLOOD; BLOOD DONOR; GENETICS; HETEROZYGOTE; METABOLISM; MUTATION; THALASSEMIA;

ALPHA-GLOBINS; BETA-GLOBINS; BLOOD DONORS; ERYTHROCYTE INDICES; ERYTHROPOIESIS; FERRITINS; HEPCIDINS; HETEROZYGOTE; HUMANS; IRON; MUTATION; THALASSEMIA;

EID: 84929075013     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12464     Document Type: Article

References (49)

1. Olivieri NF. The β-thalassemias. N Eng J Med 1999;341:99-109.
2. Rund D, Rachmilewitz E. Medical progress beta-thalassemia. N Engl J Med 2005;353:1135-46.
3. Weatherall DJ. Disorders of globin synthesis: the thalassemias. In: Lichtman MA, Beutler E, Kaushansky K, Kipps TJ, eds. Williams Hematology, 7th edn. New York: McGraw-Hill Medical; 2006:633-56.
4. Diego S, Pootrakul P, Sirankapracha P, et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000;96:2606-12.
5. Rivella S, Giardina JP. Thalassemia syndromes. In: Hoffman R, Benz EJ Jr, Silberstein L, Heslop H, Weitz J, Anastasi J, eds. Hematology: Basic Principles and Practice. Philadelphia: Elsevier; 2013:505-35.
6. Modell B, Darlison M. Global epidemiology of hemoglobin disorders and derived service indicators. Bull WHO 2008;86:480-7.
7. Kan YW. Molecular pathology of α-thalassemia. Ann NY Acad Sci 1985;445:28-36.
8. Vichinsky E. Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann NY Acad Sci 2010;1202:180-7.
9. Harteveld C, Higgs D. Alpha-thalassaemia. Orphanet J Rare Dis 2010;5:13.
10. Ramalho AS, Silva RBP, Teixeira RC, Compri MB. Hemoglobin screening: response of a Brazilian community to optional programs. Cad Saude Publica 1999;15:591-5.
11. Sonati MF, Farah SB, Ramalho AS, Costa FF. High prevalence of alpha-thalassemia in a black population of Brazil. Hemoglobin 1991;15:309-11.
12. Tavares CFF, Guimarães JS, Almeida MR, Souza AM. Hemoglobinopatias em escolares de Ribeirão Preto, São Paulo. In: Congresso Brasileiro de Hematologia e Hemoterapia, 2011, Sao Paulo, Rev Bras Hematol Hemoter 2011;33:52-52.
13. Adorno EV, Couto FD, Moura Neto JP, et al. Hemoglobinopathies in newborns from Salvador, Bahia, Northeast Brazil. Rev Saúde Públ 2005;21:292-8.
14. Alcoforado GHM, Bezerra CM, Lemos TMAM, et al. Prevalence of α-thalassemia 3.7 kb deletion in the adult population of Rio Grande do Norte, Brazil. Genet Mol Biol 2012;35:594-8.
15. Souza AES, Cardoso GL, Takanashi SYL, Guerreiro JF. α-thalassemia (3.7 kb deletion) in a population from the Brazilian Amazon region: Santarem, Para State. Genet Mol Res 2009;8:477-81.
16. Ginzburg Y, Rivella S. Β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011;118:4321-30.
17. Speeckaert MM, Speeckaert R, Delanghe JR. Biological and clinical aspects of soluble transferrin receptor. Crit Rev Clin Lab Sci 2011;47:213-28.
18. Demir A, Yarali N, Fisgin T, Duru F, Kara A. Serum transferrin receptor levels in beta-thalassemia trait. J Trop Pediatr 2004;50:369-71.
19. Li H, Ginzburg YZ. Crosstalk between iron metabolism and erythropoiesis. Adv Hematol 2010;2010:605435.
20. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60.
21. Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol Oncol Clin North Am 2010;24:1089-107.
22. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101.
23. Casanovas G, Spasic MV, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013;98:444-7.
24. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis 2011;47:232-4.
25. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92:583-8.
26. Skikne BS. Test of the month serum transferrin receptor. Am J Hematol 2008;83:872-5.
27. Fertrin KY, Lanaro C, Franco-Penteado CF, de Albuquerque DM, de Mello MRB, Pallis FR, et al. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. Am J Hematol 2014;89:385-90.
28. Dodé C, Krishnamoorthy R, Lamb J, Rochette J. Rapid analysis of -α3.7 thalassaemia and αααanti 3.7 triplication by enzymatic amplification analysis. Br J Haematol 1993;83:105-11.
29. World Health Organization. WHO information for Iron Deficiency Anaemia. Assessment, prevention, and control. A guide for programme managers. 2001. http://www.who.int/nutrition/publications/micronutrientsanaemia_iron_deficiency/WHO_NHD_01.3/en/. Accessed 20 January 2014.
30. Suominen P, Punnonen K, Rajamäki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood 1998;92:2934-9.
31. Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560-7.
32. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292-7.
33. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31:534-40.
34. Karl JP, Lieberman HR, Cable SJ, Williams KW, Young AJ, Mcclung JP. Randomized, double-blind, placebo-controlled trial of an iron-fortified food product in female soldiers during military training: relations between iron status, serum hepcidin, and inflammation 1-5. Am J Clinial Nutr 2010;92:93-100.
35. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 2011;117:2953-9.
36. Pasricha S, Mcquilten Z, Westerman M, Keller A, Nemeth E, et al. Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica 2011;96:1099-105.
37. Mast AE, Schlumpf KS, Wright DJ, Johnson B, Glynn SA, et al. Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica 2013;98:1324-30.
38. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007;109:5027-35.
39. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006;91:809-12.
40. Vichinsky E. Advances in the treatment of alpha-thalassemia. Blood Rev 2012;26(Suppl 1):S31-4.
41. Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev 2012;26(Suppl 1):S7-11.
42. Vichinsky EP. Clinical manifestations of α-thalassemia. Cold Spring Harb Perspect Med 2013;3:a011742.
43. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013;98:833-44.
44. Gardenghi S, Rivella S. New insight on the management of ineffective erythropoiesis and iron overload in β-thalassemia and related hemoglobinopathies. Hematol Educ 2012;6:331-8.
45. Li H, Rybicki AC, Suzuka SM, Bonsdorff L, Breuer W, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010;16:177-82.
46. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest 2010;120:4466-77.
47. Parrow NL, Gardenghi S, Rivella S. Prospects for a hepcidin mimic to treat β-thalassemia and hemochromatosis. Expert Rev Hematol 2011;4:233-5.
48. Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest 2013;123:1531-41.
49. Anderson ER, Taylor M, Xue X, Ramakrishnan SK, Martin A, et al. Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci USA 2013;110:E4922-30.